ES3014261T3 - Laquinimod formulation for ocular use - Google Patents

Laquinimod formulation for ocular use Download PDF

Info

Publication number
ES3014261T3
ES3014261T3 ES22718720T ES22718720T ES3014261T3 ES 3014261 T3 ES3014261 T3 ES 3014261T3 ES 22718720 T ES22718720 T ES 22718720T ES 22718720 T ES22718720 T ES 22718720T ES 3014261 T3 ES3014261 T3 ES 3014261T3
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
formulation
mpas
laquinimod
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22718720T
Other languages
English (en)
Spanish (es)
Inventor
Hans WÄNNMAN
Marie Törngren
Helena Eriksson
Andreas Buhl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Application granted granted Critical
Publication of ES3014261T3 publication Critical patent/ES3014261T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES22718720T 2021-04-01 2022-03-31 Laquinimod formulation for ocular use Active ES3014261T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21166691 2021-04-01
PCT/EP2022/058523 WO2022207773A1 (en) 2021-04-01 2022-03-31 Laquinimod formulation for ocular use

Publications (1)

Publication Number Publication Date
ES3014261T3 true ES3014261T3 (en) 2025-04-21

Family

ID=75362492

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22718720T Active ES3014261T3 (en) 2021-04-01 2022-03-31 Laquinimod formulation for ocular use

Country Status (14)

Country Link
US (1) US20240180819A1 (enExample)
EP (2) EP4461364B1 (enExample)
JP (1) JP2024516929A (enExample)
KR (1) KR20230165260A (enExample)
CN (1) CN117120035A (enExample)
AU (1) AU2022248724A1 (enExample)
BR (1) BR112023018932A2 (enExample)
CA (1) CA3212851A1 (enExample)
ES (1) ES3014261T3 (enExample)
IL (1) IL305997A (enExample)
MX (1) MX2023010971A (enExample)
PL (1) PL4312986T3 (enExample)
WO (1) WO2022207773A1 (enExample)
ZA (1) ZA202309969B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL320428A (en) 2022-11-04 2025-06-01 Qlaris Bio Inc Topical ophthalmic administration of cromolyns
CN118892446A (zh) * 2023-04-27 2024-11-05 维眸生物科技(浙江)有限公司 一种含vvn001的眼科组合物
CN119523881A (zh) * 2024-04-28 2025-02-28 中国人民解放军海军军医大学第二附属医院 一种s100a9抑制剂凝胶剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
EP3068395A4 (en) * 2013-11-15 2017-07-12 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
US9694003B2 (en) * 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
IL289109B2 (en) * 2019-06-19 2025-10-01 Tarsus Pharmaceuticals Inc Isoxazoline formulations against parasites and methods for treating blepharitis
KR20220118419A (ko) 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물

Also Published As

Publication number Publication date
AU2022248724A1 (en) 2023-11-02
MX2023010971A (es) 2023-09-27
KR20230165260A (ko) 2023-12-05
JP2024516929A (ja) 2024-04-18
US20240180819A1 (en) 2024-06-06
PL4312986T3 (pl) 2025-02-17
BR112023018932A2 (pt) 2023-10-10
CA3212851A1 (en) 2022-10-06
EP4312986B1 (en) 2024-10-23
EP4461364A3 (en) 2024-11-27
CN117120035A (zh) 2023-11-24
ZA202309969B (en) 2025-03-26
EP4312986C0 (en) 2024-10-23
EP4461364A2 (en) 2024-11-13
EP4461364B1 (en) 2026-04-22
EP4312986A1 (en) 2024-02-07
WO2022207773A1 (en) 2022-10-06
IL305997A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
ES3014261T3 (en) Laquinimod formulation for ocular use
DK2512515T3 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DRY EYES
EA034839B1 (ru) Офтальмологический раствор
ES3031414T3 (en) Ophthalmic suspension composition
BR112013007473B1 (pt) Composição farmacêutica líquida para a administração de ingredientes ativos
US11229596B2 (en) Preservative free pharmaceutical ophthalmic compositions
US12186295B2 (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
ES3008008T3 (en) Use of high molecular weight hyaluronic acid as ocular transporting vehicle
US20240165018A1 (en) Hydrogel implants for lowering intraocular pressure
KR20140069210A (ko) 안과적 겔 조성물
EA051540B1 (ru) Композиция лаквинимода для глазного применения
HK40102218A (en) Laquinimod formulation for ocular use
HK40102218B (en) Laquinimod formulation for ocular use
Jadhav et al. MICONAZOLE LONG RETENTIVE OPHTHALMIC SUSPENSION DEVELOPED WITH SODIUM ALGINATE AND CARRAGEENAN POLYMER SYSTEM
BR112017022942B1 (pt) Composições compreendendo anakinra, e seu uso